Home > Insider Trading > Filing (0001104659-21-134772)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1689375	Entrada Therapeutics Inc.	TRDA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1664281	Kush Parmar	C/O Entrada Therapeutics, Inc. 6 Tide Street Boston MA 02210		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-11-02	318,616	$0.00	649,771	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-11-02	2,371,739	$0.00	3,021,510	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-11-02	564,217	$0.00	564,217	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-11-02	254,512	$0.00	3,276,022	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-11-02	318,140	$0.00	882,357	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-11-02	250,000	$20.00	1,132,357	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series Seed Preferred Stock	Disposition	2021-11-02	318,616	$0.00	318,616	$0.00
Common Stock	Series A Preferred Stock	Disposition	2021-11-02	2,371,739	$0.00	2,371,739	$0.00
Common Stock	Series A Preferred Stock	Disposition	2021-11-02	564,217	$0.00	564,217	$0.00
Common Stock	Series B Preferred Stock	Disposition	2021-11-02	254,512	$0.00	254,512	$0.00
Common Stock	Series B Preferred Stock	Disposition	2021-11-02	318,140	$0.00	318,140	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.
Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein.
Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Kush M. Parmar, M.D., Ph.D. is a managing member of Opportunities GP and may be deemed to share voting and investment power over the shares held by Opportunities. Dr. Parmar disclaims beneficial ownership of the shares held by Opportunities except to the extent of his pecuniary interest therein.
On November 2, 2021, Opportunities purchased 250,000 shares of Common Stock of the Issuer at a price of $20.00 per share pursuant to an underwritten public offering.